The Step-Down Never Came and Lilly Lifts Its Revenue Guide $5.5B, But a 10% Two-Day Run Prices It In. Downgrading to Hold

Results vs. Consensus

Q3 2026 Scorecard

Lilly does not publish Street consensus. The comparison uses the estimates we tracked into the print. Revenue consensus was tight across providers at $22.1–22.7B. EPS consensus was not, for the same reason as last quarter: providers treated the quarter’s acquired IPR&D charge differently.

Year-Over-Year Comparison

Quarter-Over-Quarter Comparison

The sequential view tests the August debate directly, because the August guide implied quarterly revenue about 6% below Q2. Q3 came in 6% above it.

Quality of the Beat

Revenue. The composition is volume-led again. Worldwide volume rose 53% against a 15% decline in realized price. U.S. revenue grew 34% to $15.1B on 41% volume, and revenue outside the U.S. grew 47% to $9.3B on 76% volume. The release names about $900M of benefits in the quarter: $410M of Jardiance sales-based milestones from the Boehringer Ingelheim collaboration, with no further milestones remaining, and favorable adjustments to rebate and discount estimates for the balance. Strip the full $900M and revenue was about $23.5B, which still sits above Q2’s reported figure, and Q2 carried one-offs of its own. Against the most-cited $22.6B consensus, the underlying beat is roughly $0.9B, or about 4%, on the assumption that consensus carried none of the one-offs. That is a smaller beat than the headline, and it is still a beat.

Margins. Non-GAAP gross margin of 84.4% is 80bp above last year, but 190bp below Q2’s 86.3%. In August we wrote that Q2 was flattered by rebate adjustments and that we would model 84–85%; Q3 landed inside that band even though it carried adjustments of its own. Management attributed the year-over-year gain to mix and production cost, partly offset by price. Below the gross line, the operating leverage is plain: R&D grew 23% and marketing and administrative costs 14% against revenue up 39%, taking the combined ratio down 505bp to 30.2%. The performance margin of 54.2% was 5.9 points above last year and 60bp below Q2.

EPS. As-reported non-GAAP EPS grew 7% while revenue grew 39%, and the gap again sits entirely below the operating line. Acquired IPR&D was $4,181M, mostly non-deductible, which lifted the non-GAAP tax rate to 24.0% from 17.7%. Net interest expense almost tripled to $316M as debt funded the deals and the plants. Before acquired IPR&D, EPS was $12.05, up 56%. Strip the one-off revenue at roughly a 17% tax rate and the underlying figure is closer to $11.2. That is still about 45% above last year’s reported $7.73, and it is the number we capitalize.

Product and Geographic Performance

Key Products — Q3 2026

Selected Non-Key Lines

Revenue by Geography

Regional growth rates are on a constant-currency basis as disclosed. Worldwide, U.S. and ex-U.S. figures are as reported. In Q2 the corresponding regional growth rates were +55%, +30%, +93% and +136%, so every region decelerated against a harder comparison base, as management flagged in August.

Mounjaro — the international book keeps widening its lead

Mounjaro grew 65% to $10,723M. Ex-U.S. revenue of $5,725M grew 93% and is now $727M larger than the U.S. book of $4,998M, against a gap of about $0.4B in Q2. China grew 62% in constant currency, and management said Mounjaro is the first medicine to pass $1B of revenue in China in its first full year. In Japan, Mounjaro now takes more than half of new patient starts. Lilly’s share of the international incretin market rose nearly four points sequentially to about 58%.

"Lilly strengthened its leadership position outside the U.S., gaining nearly 4 percentage points of share compared to Q2 26, to reach approximately 58%." — Lucas Montarce, Chief Financial Officer

Assessment: Share is still rising, which matters more than the deceleration in growth. The international incretin market grew 53% by IQVIA gross sales, down from 74% in Q2, so Lilly is taking a bigger slice of a market that is slowing from an extreme pace. That is the right mix for the bull case. The one caution came on pricing: the United Kingdom, Lilly’s most penetrated ex-U.S. market, is already growing more slowly, which previews what the larger markets look like at maturity.

Zepbound — Medicare lifts the domestic core

Zepbound grew 49% to $5,352M, up 8.6% sequentially, the fastest quarter-on-quarter growth of the two tirzepatide brands. The U.S. obesity incretin market grew 82% in total prescriptions, up from 78% in Q2, which is the clearest sign that the Medicare GLP-1 Bridge is adding patients rather than moving them. Lilly kept about six in ten U.S. obesity prescriptions and more than seven in ten injectable ones. The release attributed the U.S. price decline primarily to Zepbound.

Assessment: In August we called Zepbound the stable, price-pressured core that funds the launches around it. The Bridge has changed that: three-quarters of Bridge patients chose an injectable, and seven in ten new Bridge patients started on a Lilly obesity medicine. Zepbound is growing again at the margin. The price that comes with Medicare volume is lower, and management said as much about 2027.

Foundayo — the volume turned, the revenue did not catch up

Foundayo booked $184M in its second full quarter, up 88% from $98M, against Street estimates of $217–229M. The leading indicators moved the right way. New patients doubled from Q2, trialists more than doubled, the drug took about four in ten U.S. oral obesity new starts and 45% of the sequential growth in oral prescriptions, and about a quarter of patients had reached a maintenance dose. Total prescriptions passed half a million in the quarter. Outside the U.S., Lilly launched in the United Kingdom, Saudi Arabia and Mexico after the UAE, received a positive CHMP opinion in the EU, and plans launches in more than 40 markets in 2027.

"Approximately 4 in 10 patients starting an oral obesity medicine choose Foundayo. And the number of new Foundayo patients in Q3 doubled from the previous quarter." — Lucas Montarce, Chief Financial Officer

The dollars per prescription are the problem. More than 500,000 prescriptions against $184M of revenue implies well under $400 per prescription, before any allowance for sampling. Most prescriptions are still at the two lowest doses.

Assessment: Our August trigger was whether the late-July inflection would carry through, and in volume it did. In revenue it fell short of the Street by a margin that matters. Four in ten oral starts is a respectable number for a later entrant, but it means the competing oral takes the majority of U.S. oral starts. The U.S. type 2 diabetes decision is due in Q4, and management noted that roughly half of U.S. GLP-1 volume is in diabetes. We keep this pillar at risk, not broken.

Oncology, Immunology and Neuroscience — doubling, with one soft spot

The five non-cardiometabolic Key Products generated $810M against $405M a year ago, growth of 100%, and 9.9% sequential growth from Q2’s $737M. Kisunla grew 175% to $193M on the expansion of P-tau217 blood testing. Jaypirca grew 59% to $228M and gained a first-line CLL label on the BRUIN CLL-313 result, which reduced the risk of progression or death by 80% against bendamustine plus rituximab. Inluriyo won approval in combination with Verzenio for ESR1-mutated advanced breast cancer.

"Inluriyo continued its impressive uptake in the metastatic breast cancer oral SERD market. Exiting Q3 with more than 60% share of new U.S. prescriptions and 40% of US total prescriptions." — Lucas Montarce, Chief Financial Officer

Assessment: The group is now 3.3% of revenue and still compounding, which supports the terminal-value argument we made in August. Two products went flat sequentially, though. Ebglyss was $202M against $201M in Q2, and Inluriyo was $73M against $75M despite a majority share of new prescriptions. A product that leads new prescriptions while revenue goes sideways is either working through gross-to-net or running into a small segment. EMBER-4 in early breast cancer, now expected in 2027, is what makes Inluriyo a large product.

Key Performance Indicators

Key Topics & Management Commentary

Overall Management Tone: Assured and more expansive than in August, with the 2026 numbers treated as settled and the conversation moved to 2027 and the next decade. The candor of the last call on soft spots gave way to a more selective emphasis: Foundayo was argued through share and patient counts rather than dollars, and the retatrutide filing dispute that management raised in August was not raised again. On business development the posture shifted from defending a rising cadence to embracing it.

1. The second-half step-down never came

In August the arithmetic of the FY26 guide implied second-half revenue of $42.2–44.2B, about $21.6B a quarter, roughly 6% below Q2. We carried that as a new bear point and wrote that Q3 would settle it. It did. Q3 revenue was $24,397M and the new $91–92B range implies Q4 revenue of $23.8–24.8B, so the second half now lands at $48.2–49.2B. The full-year midpoint rose $5.5B in one quarter.

"Based on a strong underlying performance across our portfolio, we now expect full year revenue to be between $91 and $92 billion We saw strength in the U.S. Driven by rapid uptake of the Medicare GLP-1 bridge program. And outside of the US, from strong Mounjaro performance." — Lucas Montarce, Chief Financial Officer

Assessment: Our August read was "partly conservatism, partly real." The answer was mostly conservatism. The two variables management named in January, Bridge uptake and the depth of international cash-pay demand, both broke positive. We retire the step-down concern as contained, and we take the lesson that this management team guides to what it can see, not to what it expects.

2. About $2B of 2026 revenue will not recur

The release sized Q3’s one-off benefits at about $900M. On the call, the CFO put the full-year total near $2B, made up mainly of milestones and changes in rebate and discount estimates. The Jardiance milestones are finished: the release states no further milestones remain under the Boehringer Ingelheim agreement.

"It is also worth noting that the 2026 revenue benefited from approximately $2 billion of 1-time items primarily related to milestones payments and changes in estimates for rebates and discounts that we do not expect to recur." — Lucas Montarce, Chief Financial Officer

Assessment: Volunteering this before the January guide is good disclosure, and it is also a way to set expectations for FY27. $2B is about 2% of the FY26 midpoint, and it carries near-100% margin, so it is worth roughly $1.8 per share of FY26 EPS before acquired IPR&D. Underlying FY26 earnings power is therefore nearer $41.8 than the $43.6 the guide implies. Our FY27 estimate starts from the lower base.

3. Foundayo: market share up, dollars per prescription low

The oral answered our August question in volume: new patients doubled, oral new-start share reached about four in ten, and the inflection carried through the quarter. It did not answer it in revenue: $184M against $217–229M expected. The U.S. type 2 diabetes decision, expected in Q4, is the next lever. That is a market management sized as half of U.S. GLP-1 volume, though reimbursement in diabetes takes time to build.

"I would just add we are under review for type 2 diabetes and we see that as an extraordinary opportunity for Foundayo as well. Remembering today in the US, roughly half the volume of GLP-1s is in diabetes. So that is a big market expansion." — David Ricks, Chair and CEO

Assessment: We take three points from the quarter. First, the patient curve is real. Second, the revenue per patient is low, and will stay low while most patients sit on starter doses. Third, management expects orals to show lower adherence than weekly injectables, which caps lifetime value per patient. Foundayo is a market-expansion product with a modest price, not a premium franchise. It can still be large. It is no longer the leg the bull case rests on.

4. The Medicare GLP-1 Bridge outperformed, and management wants it permanent

The Bridge started on July 1 and has already passed half a million Lilly prescriptions. About 80% of patients are new to treatment, up from 60–70% in the first weeks, and seven in ten new Bridge patients start on a Lilly obesity medicine.

"Since the July 1st launch, more than half a million people have filled a prescription for a Lilly medicine through this program. We have heard positive feedback from patients and physicians about the initial implementation." — David Ricks, Chair and CEO

Management also laid out the path to permanence: cost-effectiveness data from the pilot, then either legislation or a regulatory change, with the expectation that coverage moves into the Part D benefit for the 2028 plan year.

Assessment: This is the access pillar working better than planned, and it was one of the two named sources of upside to the guide. The risk is the end-date. The Bridge is a pilot, and the move into Part D runs through plan sponsors that have resisted obesity coverage before. Management’s confidence is reasonable but not yet backed by a decision.

5. Pricing: a point worse in the U.S., and a mix shift ahead

U.S. realized price fell 7%, flattered by favorable rebate and discount adjustments. Underlying, it fell 10%, against 9% in Q2. Ex-U.S. price fell 29%, an improvement from 36% in Q2. For 2027, management expects commercial access to stay roughly stable and coverage growth to come from Medicare and Medicaid, which carry a lower net price.

"Excluding this adjustment, U.S. price declined 10%." — Lucas Montarce, Chief Financial Officer

On international pricing, the CEO described a deliberate effort to keep obesity prices in a tighter global band than is typical for the industry, because so much of the category is consumer-paid.

"our goal because of the consumer nature of this, is to much tighter band of pricing on obesity medicines than maybe you have seen historically in other medicine categories." — David Ricks, Chair and CEO

Assessment: The trade is unchanged: price down, volume up by more. It has now worked for five consecutive quarters. What changed is that management told investors the 2027 headwind will come partly from channel mix rather than list price, which is harder to see coming in weekly prescription data. A narrower global price band also limits how much ex-U.S. markets can subsidize U.S. erosion, or the reverse.

6. International: share-take continues as growth slows

International incretin revenue growth slowed to 53% from 74% by IQVIA gross sales, while Lilly’s share rose to about 58%. Every region decelerated in constant currency, as expected given the wave of Mounjaro launches in the second half of 2025. Mounjaro passed $1B in China in its first full year, and nine European markets now reimburse type 2 diabetes use.

"Mounjaro is the first medicine in China to exceed $1 billion of revenue during its first full year." — Lucas Montarce, Chief Financial Officer

Assessment: In August we wrote that growth outside the U.S. would shift from share-take to market expansion. Q3 showed both at once, which is better than we expected. Penetration outside the U.S. is still in the low single digits by management’s account, so the runway is long. The United Kingdom, at U.S.-like penetration, is the template for where growth goes when a market matures.

7. Margins: a sequential give-back, and a Q4 guide built to be beaten

Non-GAAP gross margin fell to 84.4% from 86.3% in Q2 while staying 80bp above last year. The performance margin was 54.2%. The new full-year performance-margin guide of 52.0–52.5% is more revealing than the quarter. Nine-month performance margin was 53.2%, so the full-year range implies a Q4 performance margin of roughly 49–51%.

"Gross margin as a percentage of revenue increased 80 basis points to 84.4%, as favorable product mix and an improved cost of production were partially offset by lower realized prices." — Lucas Montarce, Chief Financial Officer

Assessment: Some of the implied Q4 drop is real: no one-off revenue, fourth-quarter launch spending, and normal year-end R&D. Most of it looks like the same posture that produced the H2 revenue guide we wrongly took seriously in August. The implied Q4 EPS of $10.59–11.59 compares with Q3’s $12.05 before acquired IPR&D, or about $11.2 without the one-offs. On our numbers, the Q4 guide asks for flat-to-down underlying earnings. We would not underwrite that as the base case.

8. Business development now absorbs free cash flow

Acquired IPR&D was $4,181M in Q3: $2,610M for AtaiBeckley’s Phase 2 synthetic 5-MeO-DMT for treatment-resistant depression, $954M for Curevo’s Phase 2 shingles vaccine, and the balance across smaller deals. Year-to-date the charge is $7,541M, or $8.12 per share. The cash view is larger. Lilly paid $18.2B for business development in the first nine months, against operating cash flow of $27.4B and capital expenditure of $8.4B, so deals consumed roughly 96% of free cash flow. Dividends of $4.6B and buybacks of $4.3B were funded largely by $7.0B of new debt and a $2.4B reduction in cash. Merida closed in October for up to $2.9B.

"the BD activity reflects just our strategic intent to grow those areas. But the intersection of that strategic intent with assets that are actually out there and that are attractive to us." — Dr. Daniel Skovronsky, Chief Scientific and Medical Officer

Assessment: We moved this risk to emerging in August because the cadence had outgrown the disclosure. It has now outgrown free cash flow, and management signaled more to come. The science is defensible deal by deal, and the balance sheet can carry it. But an investor valuing Lilly on EPS before acquired IPR&D, as we do, is ignoring a cost that has run at more than $8 per share this year. We move this bear point to materializing.

9. Retatrutide beat semaglutide head to head, and the filing dispute went unmentioned

TRANSCEND-T2D-2 compared retatrutide with semaglutide 2mg in type 2 diabetes. Retatrutide reduced A1c by 2.2% against 1.8% and delivered 20–21% weight loss against 9.4%. Lilly also issued a public call to shut down an illegal retatrutide black market, which says something about patient demand for an unapproved drug.

"what is even more striking was the 20% to 21% weight loss achieved in people taking retatrutide compared to 9.4% weight loss in the semaglutide arm." — Dr. Daniel Skovronsky, Chief Scientific and Medical Officer

Assessment: The efficacy case keeps getting stronger, and a head-to-head diabetes win widens the label argument. What was missing matters as much. In August management volunteered that the FDA classification of retatrutide as a biologic was in active litigation. This quarter neither the call, the release nor the 10-Q addressed it. Management did not restate the Q1 2027 submission target on the call.

10. The next generation: eloralintide returns, and a longer-acting gap is acknowledged

Eloralintide, which went unmentioned in August, came back in combination. EloraTZP, a co-formulation of the amylin agonist with tirzepatide, delivered 23.3% weight loss at 48 weeks in people with type 2 diabetes and obesity, and an A1c reduction of 2.9% at the top dose. Phase 3 starts in Q4 2026. The highest-dose arm had more discontinuations for adverse events, which management attributed to fast titration. ACHIEVE-4 met its non-inferiority endpoint for orforglipron against insulin glargine and showed a 16% lower risk of four-point MACE in a prespecified analysis.

"As 1 might expect, when rapidly escalating doses of a medicine with multiple mechanisms, the highest dose Olora-TZP arm had a higher discontinuation rate due to adverse events. As we move into Phase 3, we, of course, will use a slower, optimized dose escalation schedule." — Dr. Daniel Skovronsky, Chief Scientific and Medical Officer

On longer-acting incretins, which one analyst called the only hole in the pipeline, management confirmed multiple clinical programs but declined to name a lead.

Assessment: This closes one of our August omissions. The three-hormone combination is the most interesting next-generation asset after retatrutide, and the tolerability issue looks like a dosing question rather than a mechanism problem, though Phase 3 has to show it. The longer-acting gap is real, and Lilly is still choosing between platforms.

11. Capacity, capital and management change

Lilly broke ground on a $6.5B plant in Houston and a $5B plant in Richmond, Virginia. The quarter’s buyback was only $400M against $1.5B of dividends, after $3.9B of repurchases in the first half. Patrik Jonsson, president of Lilly International, retires at the end of 2026, and Ilya Yuffa adds international markets to the U.S. business as president of Lilly Global Markets. An Innovation Day focused on R&D is set for December 7.

"We broke ground on 2 new manufacturing facilities, a $6.5 billion facility in Houston, Texas and a $5 billion facility in Richmond, Virginia." — David Ricks, Chair and CEO

Assessment: The slowdown in buybacks is the clearest sign that deals and plants now compete for the same cash. Combining U.S. and international commercial leadership under one executive makes sense for a consumer-led category with a single global price band. The December event is the first chance for management to put numbers on the multi-year plan that it has so far given only in qualitative terms.

Guidance & Outlook

The EPS bridge is exact: the prior midpoint of $36.00, plus $4.07 of underlying improvement, less $4.57 of Q3 acquired IPR&D, equals the new $35.50 midpoint. Guidance still excludes acquired IPR&D incurred after September 30, so the Merida charge will lower the headline range again in January. Before acquired IPR&D, the FY26 midpoint is about $43.62, against about $39.55 implied in August.

Management also gave its first qualitative frame for 2027. On the positive side: continued incretin volume growth, a full year of Bridge access, the Foundayo diabetes launch in the U.S., and the global Foundayo rollout. On the negative side: net price as a headwind "more than offset by volume growth," and the roughly $2B of 2026 one-offs that will not repeat. Numerical FY27 guidance comes on the Q4 call in January.

Implied Q4. Revenue of $23.8–24.8B, flat at the midpoint against Q3 as reported and up about 3.5% against Q3 without its one-offs. EPS of $10.59–11.59 and a performance margin of roughly 49–51%, both below Q3’s run-rate.

Where the Street sits. FY26 revenue consensus going in was about $88.5B, so the new midpoint is about $3.0B, or 3%, above it. Consensus for Mounjaro and Zepbound was too low by 5–6% and for Foundayo too high by 15–20%. The net effect is that estimates for the injectables move up and estimates for the oral move down.

Guidance style. Lilly has raised its revenue guidance at every in-year update since we initiated, and FY26 has risen about $10B from the January range. Asked directly why guidance keeps missing to the upside, management pointed to two never-before-seen variables and said guidance should become more predictable as those variables are learned. We take the pattern at face value: the January guide will be beatable, and the Street knows it.

Analyst Q&A Highlights

Whether the guidance raises reflect a bigger market or pulled-forward demand

The opening question asked what had surprised management most across a year of raises and whether the incretin opportunity is structurally bigger or simply arriving sooner. The answer leaned on penetration: about one in ten eligible U.S. patients and two in a hundred outside the U.S. are being treated.

Q: "You have raised guidance on the top line by roughly $10 billion year to date. ... are we just seeing a fundamentally larger incretin opportunity than you anticipated? Or is this more of a pull forward of demand as we think about that kind of longer addressable TAM for the company?"
— Christopher Schott, JPMorgan

A: "You look at the US, and we are talking about 1 out of 10 patients that we are reaching nowadays ... So it is actually a really low base, though the number seems really big, $16 billion this quarter of incretin business. The runway of opportunity for growth is still years to come from my perspective."
— Lucas Montarce, Chief Financial Officer

Assessment: The penetration numbers answer the pull-forward question well enough for the injectables. They are less helpful for the price question underneath it: the next nine in ten U.S. patients will come through Medicare, Medicaid and cash pay at lower net prices than the first one did. Management answered the volume half and left the revenue-per-patient half alone.

Why the guidance keeps missing to the upside

A long-time observer of the company told management plainly that its guidance has not been a good predictor of results and asked whether the surprises come from volume, price or deliberate caution. The CEO’s answer was candid about the incentive and specific about the two variables that drove this year’s raises.

Q: "And with all due respect, Lilly's financial guidance has not been a good predictor on ultimate results. And I am curious, what is the most frequent source of the surprise? ... A key for investors, I think, is to determine when the surprise factor runs its course."
— Steve Scala, TD Cowen

A: "our goal is to give as accurate a projection as we can. But, of course, you know, there is asymmetry with missing on the downside. that is, like, everyone's impulse. But let's remember, like, we are in the middle of the largest new category expansion in the history of the pharmaceutical industry."
— David Ricks, Chair and CEO

Assessment: An admission that downside misses cost more than upside beats is as close as a CEO gets to confirming a conservative bias. The forward point matters more: management expects guidance to become more predictable as the unknowns shrink. If that happens, the beat-and-raise cycle that has supported the stock will narrow, and the multiple will have to rest on the earnings alone.

How the Foundayo launch compares with the rival oral and with plan

The question asked for an update on the oral in the U.S. and abroad, against the competing oral and Lilly’s own expectations, and raised the fact that most prescriptions are still at the two lowest doses. The international answer said launches were in line with plan; the U.S. answer led with share data.

Q: "just curious to hear any updated framing on how the launch is playing out both in the U.S. As well as internationally in the context of both competitive dynamics versus oral Wegovy and then your own internal expectations."
— Asad Haider, Goldman Sachs

A: "So our NBRx share of market is approaching around 4 out of 10. And so good progress overall for the growth of Foundayo in the oral segment and even in the sequential growth of orals within from Q2 to Q3, we are taking 45% of that growth with Foundayo."
— Ilya Yuffa, President, Lilly USA & Global Customer Capabilities

Assessment: Neither answer addressed the "internal expectations" part of the question, and for the U.S. that silence fits a quarter that missed the Street. A 40% share of new oral starts and 45% of incremental oral growth describe a strong number two, not a leader. The disclosure that about a quarter of patients have reached a maintenance dose, which management said is higher than the rival’s, is the best evidence that revenue per patient will rise from here.

What persistency looks like on injectables and what to expect from orals

An analyst asked for real-world persistency data on tirzepatide and whether the oral and retatrutide would differ. The answer on the injectable was strong. The answer on the oral was the most notable concession of the call.

Q: "I want to ask about what data you have on tirzepatide persistency in obesity just over the course of the past year or so. And importantly, when you look to next year, would you expect Foundayo and retatrutide to be different than that in terms of real world experience?"
— Geoffrey Meacham, Citi

A: "Now expectations for oral, it is still early. But as typical chronic medications has as well as if you take a look at orals, they typically are lower adherence overall relative to weekly injectable therapies. And that is what we expect to see."
— Ilya Yuffa, President, Lilly USA & Global Customer Capabilities

Assessment: Zepbound adherence tracking Trulicity’s 16–18 months, even in cash pay, is good news for the core franchise. Management expecting lower adherence on its own oral is a modelling input, not a throwaway line. Lower persistence means lower revenue per patient started, and it reinforces our view that Foundayo is a high-volume, lower-value product.

The split between injectables and pills inside the Medicare Bridge

The question asked whether the injectable-heavy mix in Medicare surprised management and how many Bridge patients are new to treatment. Both numbers moved from August: the injectable share fell slightly and the share of new patients rose.

Q: "How does the split between injectable and pill and how does that mix look different from others? It seems by the majority of Medicare demand is injectable. I wonder if that surprised you with regard to your products in that space."
— Kerry Holford, Berenberg

A: "we have seen about 3 quarters, 75% of people coming into Bridge going into injectable therapy. 7 out of 10 in total choosing a Lilly medicine."
— Ilya Yuffa, President, Lilly USA & Global Customer Capabilities

Assessment: In August we called the 80% injectable preference the cleanest natural experiment on the oral: equal access, equal cost, free choice. At 75% it has moved a little toward the pill, which slightly weakens our bear argument on Foundayo. Seven in ten Bridge patients choosing Lilly confirms that the program favors the market leader, and the rise in new-to-treatment patients to about 80% confirms it is growing the market.

Whether 2027 U.S. pricing gets worse through channel mix

An analyst asked whether employer coverage trends and Bridge growth would shift the U.S. channel mix in 2027 and push pricing below the mid-teens decline absorbed in 2026. The answer described a mix effect, not a list-price cut.

Q: "could your US channel mix meaningfully evolve next year? So it potentially creates additional pricing pressure amongst the mid teens decline that you have absorbed in 2026. Or could we see pricing headwinds in the same range for 2027?"
— Analyst, RBC Capital Markets

A: "The main access improvements overall for 2027 will most likely be predominantly growth of Medicare. And Medicaid as opportunities for expanded coverage. That will have a segment mix more towards a lower price, a lower net price, not decreasing the price overall, but more just a segment mix."
— Ilya Yuffa, President, Lilly USA & Global Customer Capabilities

Assessment: Management did not say whether the 2027 decline would be larger or smaller than this year’s, which was the question. It did say the coverage growth will come from the lowest-priced channels while commercial access stays flat. For the revenue line, a mix shift and a price cut have the same effect. We assume a 2027 U.S. price decline at least as large as 2026’s.

Whether the Medicare Bridge survives past its pilot window

The question asked whether conversations with the administration or Part D sponsors support an extension. The CEO gave three reasons for optimism and a specific path.

Q: "Have you had conversations with the admin or the various Plan D sponsors that give you confidence this program will either be extended or balance will be revisited in a different iteration."
— Carter Gould, Cantor Fitzgerald

A: "But I think all signals now point to a pretty successful cost effectiveness which could yield either a legislative or a regulatory shift in the coverage permanently. In the meantime, I think there is a lot of energy with the people running CMS at current point to continue this, and the right way to do that is put this into the Part D benefit."
— David Ricks, Chair and CEO

Assessment: The answer was confident and conditional. It rests on cost-effectiveness data that CMS has yet to publish, and on Part D plans that have historically resisted obesity coverage. Management suggested revisiting the topic on the Q1 2027 call, which puts the Bridge’s permanence on the calendar as a 2027 catalyst rather than a settled fact.

How Lilly keeps the bar high as deal-making accelerates

The final question asked where the portfolio stands on risk and reward after a rapid pace of acquisitions and how the bar is kept high. The answer embraced risk and promised more transactions.

Q: "Can you just help us understand where you believe you are at in terms of the risk reward balance across your portfolio, the types of areas that might be of interest to continue adding, and how you are kind of ensuring that you are keeping the bar high."
— Courtney Breen, Bernstein

A: "Risk is really our friend here. Risk allows us to actually create value. And 1 of the ways we can deploy that for the reasons we can is because we do not need revenue tomorrow."
— Jacob Van Naarden, President, Lilly Oncology and Head of Business Development

Assessment: A strategic case for buying earlier-stage risk while the incretin business throws off cash is coherent. The answer also said some deals are not press-released and that "you will see more of both of those categories from us." That is the opposite of the annual envelope we asked for in August. Investors get a promise of discipline deal by deal, with no total.

What They’re NOT Saying

1. Nothing on the retatrutide classification dispute. In August management disclosed that the FDA’s view of retatrutide as a biologic or a small molecule was in active litigation, which decides five versus twelve years of exclusivity. This quarter the call, the release and the 10-Q were all silent on it, and management did not restate the Q1 2027 submission target in its own words.
2. No full split of the $900M of one-offs. The release names the $410M of Jardiance milestones and attributes the rest primarily to rebate and discount adjustments, roughly $490M by subtraction. It does not say how much of the roughly $2B full-year total fell in each quarter or whether any of it sits in the Q4 guide.
3. No Foundayo revenue split or net price. Share, patient and prescriber data were plentiful. U.S. versus international revenue, net price per prescription and the contribution to the raised guide were not given, in the second consecutive quarter the product fell short of the Street.
4. No business-development envelope, again. Nine-month deal cash of $18.2B equalled free cash flow and Merida adds up to $2.9B. Management said more deals are coming, some not press-released, and gave no annual budget or aggregate figure.
5. No explanation of the implied Q4 margin. The full-year performance-margin guide implies Q4 at roughly 49–51% against Q3’s 54.2%. Nobody asked and management did not volunteer how much of that is seasonality, launch spending or caution.
6. No comment on rising interest cost. Net interest expense rose to $316M from $114M a year ago as total debt reached $49.5B. With deals and plants now competing for cash, financing cost has become a real line in the earnings bridge.
7. No name for the impaired molecule. The $303M special charge was primarily a partial impairment of an intangible asset tied to a molecule in development. The release does not say which one.
8. No numbers for 2027. The pushes and pulls were qualitative. Investors who want a revenue or margin range wait until January, and the December Innovation Day is billed as an R&D event.

Market Reaction

• Pre-print setup: the stock closed at $1,288.30 on October 28, up 19.9% year-to-date against the S&P 500’s 13.1%, up 58.4% over the trailing twelve months and up 8.8% over the prior 30 days. The 52-week closing range was $813.53 to $1,306.69, so the stock entered the print within 2% of its high.
• Reaction session (October 29, before the open): opened at $1,332.73, a gap of +3.4%, traded between $1,330.00 and $1,408.38 (+3.2% to +9.3%), and closed at $1,373.70, up 6.6% or $85.40.
• Next-day session (October 30): opened at $1,428.83, traded between $1,408.36 and $1,449.68, and closed at $1,417.54, up a further 3.2% or $43.84. Over two sessions the stock gained 10.0%.
• Volume: 4.4M shares on the reaction day against a 2.3M 30-day average (1.9 times), and 5.0M on the following day (about 2.2 times).
• Benchmark: the S&P 500 fell 0.3% on October 29 and 1.8% on October 30. The entire move was stock-specific, and the second day came against a sharply falling market.

A momentum print, not a relief rally. In August the stock entered the print near its lows and the reaction recovered a drawdown. This time it entered near its highs after a strong month, and it still added 10% in two sessions to close at a new 52-week high. Markets do not usually do that with a beat that was partly expected; they do it when the size of the raise changes the out-year numbers. A $5.5B midpoint raise, in the quarter that was meant to show a step-down, did that.

The second day said more than the first. The first session followed a familiar pattern: an opening gap, an intraday high of +9.3%, and a close that gave back nearly a third of the gain as the Foundayo miss and the higher deal charge were absorbed. The second session reversed that: a 4.0% opening gap and a 3.2% gain while the index fell 1.8%. That looks like institutional repositioning after a round of higher estimates and price targets, not a fading first-day reaction.

What the tape looked past. The headline EPS range fell $0.50 at the midpoint and the oral missed by up to a fifth. The market treated both as noise next to the injectable beat and the size of the revenue raise. On the deal charge we agree with the market. On Foundayo we think it was right to look past the quarter but may be too relaxed about what lower revenue per patient means for 2027 and 2028.

Street Perspective

Debate: How much upside is left in a guide that is always beaten?

Bull view: Lilly has raised at every reporting date, FY26 revenue is up about $10B from the January range, and the Q4 guide implies flat-to-down underlying earnings that the company has every incentive to beat. The January FY27 guide will likely start low and rise through the year, as every guide has since the obesity launch.

Bear view: the two variables that drove this year’s raises, Bridge uptake and international cash-pay depth, are now in the base. The roughly $2B of 2026 one-offs comes out of next year’s comparison, price pressure moves into lower-paying channels, and management itself expects guidance to become more predictable. The beats get smaller from here.

Our take: both are right about different things. The January guide will likely be beatable, and management confirmed the asymmetric incentive. But the size of the beats is set to shrink as the novel variables become known, and the stock has already moved to price this quarter’s raise. Our FY27 estimate sits above where we expect the initial guide to land, so we are not counting on surprise to carry the multiple.

Debate: Is Foundayo a slow starter or a structural number two?

Bull view: patients doubled in a quarter, the oral now takes about four in ten new oral starts, international launches are tracking plan, a quarter of patients are at maintenance doses, and the U.S. diabetes indication arrives next. Revenue per patient rises as titration matures and as the 2027 international rollout reaches more than 40 markets.

Bear view: the competing oral still takes the majority of U.S. starts, revenue per prescription is low, management expects lower adherence on orals than on injectables, and the product has missed Street estimates in both full quarters since launch. The oral is expanding the category for both companies rather than winning it for one.

Our take: the bear has the better of the revenue argument and the bull has the better of the volume argument. We no longer treat the oral as a premium franchise. We treat it as a lower-priced market-expansion product that can still reach multi-billion scale through diabetes and international volume. That is a smaller contribution than the bull case assumed in May, and it is already in our numbers.

Debate: Is business development building the next decade or leaking earnings?

Bull view: Lilly is using incretin cash to buy earlier-stage risk across neuroscience, immunology, oncology and vaccines while it does not need the revenue. The deals are individually sensible, the balance sheet can carry them, and the acquired IPR&D charge is an accounting treatment for an investment in growth.

Bear view: nine-month deal cash matched free cash flow, debt is up $7.0B this year, buybacks have slowed to a trickle and the company has said there is more to come without a budget. A charge that has run at more than $8 per share in a year is not an exceptional item.

Our take: the strategy is defensible and the disclosure is not. We value the company on EPS before acquired IPR&D because that is how Lilly itself guides, but we no longer accept that the charge is incidental. If acquired IPR&D runs at 2.5% of revenue in FY27, our estimate falls by about $3 per share. We move the bear point to materializing.

Debate: After 10% in two sessions, is the stock still a buy?

Bull view: price targets moved up broadly after the print, many into the $1,500s and $1,600s. Earnings before acquired IPR&D are growing at more than 20% into FY27, a multiple in the high 20s is reasonable for that growth, and a 12-month view rolls toward FY28 earnings.

Bear view: the stock trades at about 27x FY27 earnings before acquired IPR&D and closer to 29x if the charge is normalized. It is up 32% this year, and the next catalysts are a guide that will start conservatively, an R&D day, and a retatrutide filing that has a legal question attached.

Our take: the fundamentals justify a premium, and the price now reflects it. On the same multiple band we have used all year, the stock sits above our fair value. On FY28 estimates the 12-month return looks close to what we would expect from the index. We downgrade to Hold on valuation, not on the thesis.

Model Update & Valuation Framework

Valuation math. At the October 30 close of $1,417.54 the stock trades at 39.9x the guided FY26 midpoint of $35.50, 32.5x FY26 EPS before acquired IPR&D of about $43.60, and 27.0x our FY27 estimate of about $52.5. The fair-value range of $1,225–1,400 is the same 23.5–26.5x multiple band we have applied to FY27 all year, now on the higher estimate. Its midpoint of about $1,310 sits 7.4% below the close, and the top of the range sits about 1% below it.

The FY28 cross-check. A 12-month horizon rolls toward FY28, and we tested that roll explicitly rather than using it to stretch the FY27 multiple. Our FY28 estimate before acquired IPR&D is about $61. The same 23.5–26.5x band gives $1,434–1,617, a midpoint near $1,525. That is about 7.6% above the close, plus a dividend yield of about 0.5%. A return of roughly 8% over twelve months is what we would expect from the index, not a reason to expect outperformance.

The acquired IPR&D sensitivity. Our estimates exclude acquired IPR&D, consistent with how Lilly guides. If the charge runs at 2.5% of revenue in FY27, about $2.7B and largely non-deductible, FY27 EPS on Lilly’s own as-reported basis falls to about $49.5 and the multiple at the current price rises to about 28.6x. The deal pace this year makes that a reasonable middle case, not a stress case.

Why Hold and not Outperform. In August we kept Outperform with about 5% upside to our midpoint and gave three reasons: the stock had already de-rated, a 12-month horizon rolls toward FY28, and retatrutide was carried at a probability weight. The first reason has reversed, with the stock now 21 points ahead of the index this year. The second we have now tested, and it points to a market-like return. The third remains, but the classification question has not moved. Our August triggers do not drive this change. The Foundayo test passed on volume and not on revenue, and the higher-range trigger needed both a second-half beat, which arrived, and a retatrutide classification resolution, which did not. The downgrade is about price.

What would bring us back to Outperform. A pullback toward the low end of the range, near $1,250, with the thesis intact. A January FY27 guide that implies EPS before acquired IPR&D above $55, the top of our range. Or a clean resolution of the retatrutide classification, which would justify a higher multiple on the out-years.

Thesis Scorecard Post-Earnings

Scored against the standing pillars carried in the August note, not a fresh set.

Overall: the standing thesis is strengthened on operations and weakened on capital allocation. Six of eight bull pillars were confirmed, three of them strengthened, and the bear point we added in August was resolved within one quarter. Foundayo stayed at risk: it did what we asked in volume and fell short in revenue. The business-development risk moved to materializing, the first bear point to reach that status since initiation. The business is worth more than it was in August. The stock has moved further than our estimate of that value.

Action: Downgrade to Hold from Outperform; fair value $1,225–1,400. We would hold existing positions and not add at current levels. We would revisit Outperform on a pullback toward $1,250, on a January FY27 guide that implies EPS before acquired IPR&D above $55, or on a clean resolution of the retatrutide classification. We would move to Underperform on sequential Foundayo stagnation in Q4 alongside a delayed diabetes decision, or on FY27 deal spending that again exceeds free cash flow with no envelope disclosed.